Trazodone is classified as a serotonin antagonist and reuptake inhibitor, commonly abbreviated as SARI. It belongs to the broader category of antidepressants but works differently from the more familiar SSRIs (like sertraline or fluoxetine) or older tricyclic antidepressants. The FDA labels it as “an antidepressant chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents,” which reflects its unique position among psychiatric medications.
What “SARI” Actually Means
The SARI label describes two things trazodone does simultaneously in the brain. First, it blocks certain serotonin receptors (specifically the 5-HT2A and 5-HT2C subtypes), preventing serotonin from activating them. Second, it inhibits the reuptake of serotonin, meaning it slows down the process by which nerve cells reabsorb serotonin after releasing it. The net effect is a shift in how serotonin signals move through the brain.
What makes trazodone unusual is the strength of these two actions relative to each other. Its binding to the 5-HT2A receptor is roughly ten times stronger than its binding to the serotonin transporter responsible for reuptake. This imbalance is why trazodone behaves so differently at low doses versus high doses, and why it ended up being prescribed for two very different purposes.
How It Differs From SSRIs
SSRIs like fluoxetine and sertraline primarily do one thing: block serotonin reuptake. This raises serotonin levels broadly across the brain. Trazodone also blocks reuptake, but that effect is comparatively weak. Its dominant action, blocking the 5-HT2A receptor, is something SSRIs don’t do at all. This receptor-blocking activity is linked to sedation and reduced anxiety, which explains why trazodone feels so different from a typical SSRI.
Trazodone also partially activates another serotonin receptor (5-HT1A), behaving as a partial agonist there. This is a feature it shares with buspirone, an anti-anxiety medication, and it likely contributes to trazodone’s calming effects. SSRIs lack this direct receptor activation.
Why Trazodone Is So Sedating
The strong sedation that most people notice with trazodone comes from its receptor-blocking profile. At low doses, the drug primarily blocks 5-HT2A receptors and histamine receptors, both of which promote wakefulness when activated. Because these are the strongest binding targets, they get occupied first, even at small doses. The serotonin reuptake inhibition that produces antidepressant effects requires higher doses to become meaningful.
This dose-dependent behavior is clinically important. At 25 to 150 mg, trazodone acts mostly as a sedative. At the full antidepressant dose range of 150 to 400 mg per day, the reuptake inhibition kicks in strongly enough to treat depression. The drug reaches peak blood levels about one hour after taking it on an empty stomach, or about two hours with food, which is why the sedative effect hits relatively quickly. Its half-life runs between 5 and 9 hours, long enough to cover a night of sleep but short enough that most people don’t feel heavily groggy the next morning.
FDA-Approved Use vs. Common Practice
Trazodone is FDA-approved for the treatment of major depressive disorder. That is its only officially labeled indication. In practice, though, it is one of the most commonly prescribed medications for insomnia in the United States, used at those lower doses where sedation is the primary effect.
The evidence for trazodone as a sleep aid is mixed. A meta-analysis of seven randomized controlled trials involving 429 patients found that trazodone did not significantly improve sleep efficiency compared to placebo. However, patients taking trazodone reported better subjective sleep quality, meaning they felt they slept better even when objective measurements didn’t show a dramatic change. Trazodone also reduced the number of nighttime awakenings compared to placebo. It did not significantly change how long it took to fall asleep or total sleep time in those trials.
Despite these modest results, trazodone remains popular for insomnia partly because it avoids the dependency concerns associated with benzodiazepines and Z-drugs like zolpidem.
Not a Controlled Substance
If you’re wondering whether trazodone is a controlled substance, it is not. The DEA does not schedule trazodone, meaning it has no recognized potential for abuse or dependence under federal drug scheduling. This sets it apart from many other sleep medications, including benzodiazepines (Schedule IV) and some newer sleep aids. Your pharmacy can dispense refills without the restrictions that apply to controlled substances.
Notable Side Effects
The most common side effects of trazodone, drowsiness, dizziness, and lightheadedness, stem directly from its receptor profile. The blocking of certain receptors that regulate blood vessel tone can cause a drop in blood pressure when standing up, which is why dizziness tends to be worse when getting out of bed.
The most serious rare side effect is priapism, a prolonged and painful erection unrelated to sexual arousal. Trazodone is the most commonly reported cause of drug-induced priapism, accounting for about 16% of all reported cases. The actual incidence is low, estimated at between 1 in 1,000 and 1 in 10,000 patients, with most cases occurring within the first month of starting the medication. Priapism is a medical emergency that requires immediate treatment to prevent permanent damage.
Because trazodone increases serotonin activity, combining it with other serotonin-boosting medications (including SSRIs, SNRIs, certain migraine drugs, or the herbal supplement St. John’s wort) raises the risk of serotonin syndrome, a potentially dangerous condition involving agitation, rapid heart rate, high body temperature, and muscle rigidity. The liver processes trazodone through a specific enzyme pathway, so drugs that inhibit that pathway can increase trazodone levels in the blood and intensify both its therapeutic and side effects.